表紙
市場調查報告書

膀胱過動症:開發中產品分析

Overactive Bladder - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 192758
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
膀胱過動症:開發中產品分析 Overactive Bladder - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 120 Pages
簡介

所謂膀胱過動症是膀胱的儲存機能發生問題,讓人突然感到尿意的疾病。這種情況下非常難抑制尿意,結果甚至可能造成不自主排尿(尿失禁)。其他症狀有一晚感到2∼3回尿意起床。主要治療方法有改善生活習慣、透過藥物治療緩和膀胱活動,防止失禁等。

本報告提供全球各國治療膀胱過動症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

膀胱過動症概要

治療藥的開發

  • 膀胱過動症開發中產品:概要
  • 各企業開發中的膀胱過動症治療藥
  • 大學/研究機關研究中的膀胱過動症治療藥
  • 膀胱過動症治療藥:開發中的產品一覽(各企業)
  • 膀胱過動症治療藥:研究中的產品一覽(各大學/研究機關)

膀胱過動症:治療藥的評估

  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

膀胱過動症開發治療藥的企業

  • Addex Therapeutics Ltd
  • Allergan Plc
  • 旭化成製藥
  • Astellas Pharma Inc.
  • Dompe Farmaceutici SpA
  • Dong-A ST Co., Ltd.
  • FemmePharma Global Healthcare Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Hydra Biosciences Inc
  • Ion Channel Innovations LLC
  • Ipsen SA
  • Jeil Pharmaceutical Co Ltd
  • Juniper Pharmaceuticals Inc
  • Kissei藥品工業
  • 杏林藥業
  • Lipella Pharmaceuticals Inc
  • Merck & Co Inc
  • Mezzion Pharma Co Ltd
  • 小野藥品工業
  • Recordati SpA
  • Roivant Sciences Ltd
  • Sanofi
  • Seoul Pharma Co Ltd
  • Taris Biomedical LLC
  • TheraVida Inc
  • Toray Industries
  • XuanZhu Pharma Co Ltd

藥物簡介

膀胱過動症治療藥:開發暫停的產品

膀胱過動症治療藥:開發中止的產品

膀胱過動症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11780IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H2 2019, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 6, 7, 4, 1, 10, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Overactive Bladder - Overview
    • Overactive Bladder - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Overactive Bladder - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Overactive Bladder - Companies Involved in Therapeutics Development
    • Aetas Pharma Co Ltd
    • Allergan Plc
    • Astellas Pharma Inc
    • Dare Bioscience Inc
    • DelNova Inc
    • Dompe Farmaceutici SpA
    • Dong-A ST Co Ltd
    • DongKoo Bio & Pharma Co Ltd
    • Evestra Inc
    • FemmePharma Global Healthcare Inc
    • Hydra Biosciences Inc
    • Ion Channel Innovations LLC
    • J2H Biotech
    • Kissei Pharmaceutical Co Ltd
    • KYORIN Holdings Inc
    • Kyorin Pharmaceutical Co Ltd
    • Medytox Inc
    • Merck & Co Inc
    • Mezzion Pharma Co Ltd
    • Outpost Medicine Ltd
    • Recordati SpA
    • Revance Therapeutics Inc
    • Taiho Pharmaceutical Co Ltd
    • Taris Biomedical LLC
    • TheraVida Inc
    • Velicept Therapeutics Inc
    • Veru Inc
    • XuanZhu Pharma Co Ltd
  • Overactive Bladder - Drug Profiles
  • Overactive Bladder - Dormant Projects
  • Overactive Bladder - Discontinued Products
  • Overactive Bladder - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Overactive Bladder, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Overactive Bladder - Pipeline by Aetas Pharma Co Ltd, H2 2019
  • Overactive Bladder - Pipeline by Allergan Plc, H2 2019
  • Overactive Bladder - Pipeline by Astellas Pharma Inc, H2 2019
  • Overactive Bladder - Dormant Projects, H2 2019
  • Overactive Bladder - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Overactive Bladder - Dormant Projects, H2 2019 (Contd..2), H2 2019
  • Overactive Bladder - Dormant Projects, H2 2019 (Contd..3), H2 2019
  • Overactive Bladder - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Overactive Bladder, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019